


**PRODUCT: MSC-2530818****ALTERNATE NAMES:** [(2S)-2-(4-Chlorophenyl)pyrrolidin-1-yl]-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)methanone**CATALOG NUMBER:** B1975-1, 5**AMOUNT:** 1 mg, 5 mg**STRUCTURE:****MOLECULAR FORMULA:** C<sub>18</sub>H<sub>17</sub>ClN<sub>4</sub>O**MOLECULAR WEIGHT:** 340.81**CAS NUMBER:** 1883423-59-3**APPEARANCE:** Crystalline solid**SOLUBILITY:** DMSO**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20 °C. Protect from air and light

**DESCRIPTION:** MSC-2530818 is a potent, selective CDK8 Inhibitor (IC<sub>50</sub> = 2.6 nM). It displays potent inhibition of phospho-STAT1<sup>SER727</sup>, an established biomarker of CDK8 activity. MSC2530818 demonstrates potent inhibition of WNT-dependent transcription in human cancer cell lines that have constitutively activated WNT signaling.

**REFERENCES:** Czodrowski, P., *et al.* (2016). *J. Med. Chem.* **59**, 9337-9349.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**

AT-9823 (Cat. No. 2432-5, 25)

Aurora Kinase B Inhibitor (Cat. No. 1583-5, 25)

AZD1480 (Cat. No. 2315-1, 5)

CCT-129202 (Cat. No. B1934-5,25)

CCT-137690 (Cat. No. B1935-5,25)

CP-690550 (Cat. No. 1622-5, 25)

CYC-116 (Cat. No. B1936-5,25)

Danusertib (Cat. No. B1937-5,25)

ENMD-2076 (Cat. No. B1938-5,25)

Lestaurtinib (Cat. No. 1805-500, 1000)

MLN8237 (Cat. No. 2718-5,25)

LLL12 (Cat. No. 1792-5, 25)

MS-1020 (Cat. No. 1911-1)

PF-03814735 (Cat. No. B1257-1,5)

Reversine (Cat. No. 1851-1, 5)

Ruxolitinib, free base (Cat. No. 2139-5, 25)

Tozasertib (Cat. No. 1595-25, 100)

EZSolution™ Tozasertib (Cat. No. 1803-

TC-S 7010 (Cat. No. B1203-5,25)

TG101348 (Cat. No. 2314-1, 5)

Tyrphostin AG 490 (Cat. No. 1570-5)

WHI-P131 (Cat. No. 1853-5, 25)

WP1066 (Cat. No. 1809-5, 25)

**USAGE:** *FOR RESEARCH USE ONLY! Not to be used in humans*